Medicina
Departamento
Royal Marsden Hospital
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de Royal Marsden Hospital (39)
2024
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
European Urology
-
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
European Journal of Cancer
2021
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 5, pp. 643-654
-
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Blood, Vol. 138, Núm. 18, pp. 1768-1773
2020
-
Cabazitaxel in metastatic prostate cancer
New England Journal of Medicine
-
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)
Cancer Medicine, Vol. 9, Núm. 1, pp. 116-124
-
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Blood, Vol. 136, Núm. 10, pp. 1134-1143
2019
-
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
The Lancet Oncology, Vol. 20, Núm. 8, pp. 1109-1123
-
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 20, Núm. 3, pp. 420-435
2018
-
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 1, pp. 87-100
-
Reply to 'the St Gallen international expert consensus on the primary therapy of early breast cancer 2017: Te point of view of an international panel of experts in radiation oncology' by Kirova et al.
Annals of Oncology
2017
-
De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Annals of Oncology, Vol. 28, Núm. 8, pp. 1700-1712
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
2016
-
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy
European Journal of Cancer, Vol. 56, pp. 85-92
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials
The Lancet, Vol. 386, Núm. 10001, pp. 1353-1361
-
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer
European Journal of Cancer
-
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
Breast Cancer Research, Vol. 17, Núm. 1